Arcturus

Arcturus to start Phase II trial of ARCT-2601 next quarter

Arcturus intends to initiate Phase II testing of its ARCT-2601 drug candidate next quarter. The company anticipates releasing preliminary results in the second half of 2027, following a 38-fold improvement in potency for the LUNAR 2.0 program.

Nov 6, 2026, 1:05 AM ET

Illustration for the Health desk

Learn the basics

New to this? Read: Reading a stock chart

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.